ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Medicenna Therapeutics Corporation (QB)

Medicenna Therapeutics Corporation (QB) (MDNAF)

1.90
0.07
(3.83%)
Closed May 15 4:00PM

Professional-Grade Tools, for Individual Investors.

MDNAF News

Official News Only

MDNAF Discussion

View Posts
2H2 2H2 3 weeks ago
MDNAF is a presenter at ASCO. Huge news!
πŸ‘οΈ0
2H2 2H2 1 month ago
Great presentation at ASCO
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
It is what they all say about stonks trading on Cromwell Coulson’s stonk market
πŸ‘οΈ0
2H2 2H2 3 months ago
Relishing soon. This will be 10x current value this year
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
Delisted from Nasdaq
Gee, it sure is great to watch the price of a stock I bought at $400 a share advance to a 52=week high
πŸ‘οΈ0
2H2 2H2 3 months ago
Getting legs here. Train leaving.
πŸ‘οΈ0
axelvento axelvento 6 months ago
Cash runway extended through multiple data readouts and into Q1 of calendar 2025

MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic and melanoma cancer patients, respectively

https://ir.medicenna.com/news-releases/news-release-details/medicenna-therapeutics-reports-second-quarter-fiscal-2024
πŸ‘οΈ0
Renee Renee 6 months ago
MDNA changed to MDNAF. Delisted from the Nasdaq to the OTC.

https://otce.finra.org/otce/dailyList?viewType=Additions
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
MDNA new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
MDNA new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
MDNA NEW 52 week low
πŸ‘οΈ0
Investopotia Investopotia 2 years ago
Medicenna Therapeutics $MDNA highlighted in Midas Letter/BioPub interview: Top Stocks to Buy Now? 3 Biotech Stocks for your Watchlist
πŸ‘οΈ0
EagleD EagleD 3 years ago
Going much higher. Double digits in a few months
πŸ‘οΈ0
EagleD EagleD 3 years ago
Nice after hours action, Just made 20,000. Yadda Yadda Yadda.

Nobody is here listening to me. THis one is going to be a beast tho
πŸ‘οΈ0
EagleD EagleD 4 years ago
FDA meeting Tuesday. Seems like we'll know sometime in October the results
πŸ‘οΈ0
EagleD EagleD 4 years ago
This is my largest holding -- ever. Lots of value to be unveiled here in the coming months.
πŸ‘οΈ0
Renee Renee 4 years ago
MDNA moved from the OTC to the Nasdaq:

https://otce.finra.org/otce/dailyList?viewType=Deletions
πŸ‘οΈ0
tykundegex tykundegex 5 years ago
Just stumbled onto this co.. was doing some research. Great interim results in their Phase2b! Encouraging grants in the past, and prestigious medical centers for their trials. I may nibble to create a starting position here.

I can't find any webinars or conf call recordings that the company has given, do you know if any exist?
πŸ‘οΈ0
BioSpecialist BioSpecialist 7 years ago
Nice move yesterday ..

Small Phase 2b trial has huge chance to be successful because it was already successfull in prior studies so this stock like to be above $10 after phase 2 results in early Q1 . And that Management holding 15+ million shares of the 24.3 million shares outstanding makes me also optimistic .GL


MDNA55 is enrolling patients in a Phase 2b clinical trial for rGB at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGB, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment,


Medicenna Phase 2b trial using Brainlab technology
http://www.biotuesdays.com/briefs/2017/6/8/medicenna-phase-2b-trial-using-brainlab-technology

The current Phase 2b clinical trial plans to enroll 43 adult patients with rGB at leading brain cancer centers in the U.S.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock